KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 4707 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02. PMID 41260264 · Ann Oncol · 2026-Mar 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer. PMID 41260263 · Ann Oncol · 2026-Mar 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial. PMID 41260259 · Ann Oncol · 2026-Mar 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Two-Stage Estimation of Overall Survival in the Phase 3 CheckMate 9ER Trial, Adjusting for the Impact of Subsequent Therapy. PMID 41239083 · Oncol Ther · 2026-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Population pharmacokinetics and exposure-response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study. PMID 41222125 · Br J Clin Pharmacol · 2026-Mar 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 1 Figure · 6 Panel · risk unclear
Treosulfan-Based Conditioning Ameliorates the Impact of Pretransplantation Measurable Residual Disease-Positivity in Acute Myeloid Leukemia Patients Allografted in Remission. PMID 41083020 · Transplant Cell Ther · 2026-Mar The record describes a real-world analysis that references a Phase III trial but does not present original results from a randomized trial with a drug-containing intervention. It is a retrospective single-arm study.
H S B
严格 v3 独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Strategies to address non-proportional hazards between survival curves - Lessons from phase III trials in hepatocellular carcinoma. PMID 40992574 · J Hepatol · 2026-Mar 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 1 Figure · 4 Panel · risk visible
Comprehensive Safety and Efficacy Evaluation of Immunotherapy Combination Approaches Versus Tyrosine Kinase Inhibitor Monotherapy as First-Line Treatment of Hepatocellular Carcinoma: A Network and Individual Patient Data (IPD) Meta-Analysis. PMID 42449661 · Cancers (Basel) · 2026-Jun-30 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Consolidation thoracic radiotherapy following quadruple induction with benmelstobart, anlotinib, and chemotherapy for extensive-stage small cell lung cancer: rationale and protocol of a phase II study. PMID 42433250 · Transl Lung Cancer Res · 2026-Jun-30 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Multitask learning of longitudinal circulating biomarkers and clinical outcomes: identification of optimal machine-learning and deep-learning models. PMID 42381014 · BMC Med Inform Decis Mak · 2026-Jun-30 This is a secondary analysis using data from the SQUIRE trial to evaluate machine learning methods for predicting survival from biomarkers. It is not the original formal result report of the trial's primary or key secondary efficacy endpoint.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term outcomes of adjuvant metronomic capecitabine in locoregionally advanced nasopharyngeal carcinoma: a randomized, controlled, multicenter, phase 3 study. PMID 42380630 · Nat Cancer · 2026-Jun-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Validation of the newly introduced Deauville Score 5a in patients treated for advanced-stage classic Hodgkin Lymphoma. PMID 42379221 · Blood Adv · 2026-Jun-30 The record describes a secondary, prognostic analysis of imaging biomarkers (Deauville score) within cohorts from randomized Phase III trials, but it is not a primary report of the trial's drug intervention efficacy. The analysis compares prognostic subgroups, not treatment arms. Therefore, it does not meet the criterion for being an original formal-result report of a drug intervention.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database. PMID 42373605 · Blood Cancer J · 2026-Jun-29 The report is a secondary analysis of an observational database, not the primary report of a randomized controlled trial. While it discusses a randomized Phase III trial (VERONA) for context, the analysis presented is of non-randomized treatment groups (HMA monotherapy vs HMA/VEN) from a real-world cohort. Therefore, it does not meet the requirement for an original formal-result report of a randomized trial.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China. PMID 42218899 · Lancet · 2026-Jun-27 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial. PMID 42214392 · Lancet · 2026-Jun-27 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events. PMID 42362563 · NPJ Breast Cancer · 2026-Jun-26 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Beyond the "cold" barrier: Redefining the clinical paradigm of immune checkpoint inhibitor therapy in ovarian cancer. PMID 42362076 · Crit Rev Oncol Hematol · 2026-Jun-26 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer. PMID 42361282 · J Clin Oncol · 2026-Jun-26 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer. PMID 42360104 · Clin Cancer Res · 2026-Jun-26 The record reports a secondary analysis (identifying variables associated with early detriment) from two Phase III randomized trials (CheckMate 227 and 9LA). While the underlying trials are eligible, this specific publication is not a primary report of an original efficacy endpoint. The abstract focuses on rapid progression rates and biomarker associations, not on presenting Kaplan-Meier survival curves or hazard ratios for the primary trial endpoints. Therefore, it does not meet the criterion of being an original formal-result report with a primary/key secondary time-to-event efficacy endpoint.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Stereotactic Body Radiation Therapy Combined With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Comprehensive Single-Arm Meta-Analysis Approach. PMID 42330156 · Am J Clin Oncol · 2026-Jun-26 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Para-Aortic Lymph Node Staging and Oncologic Outcomes in Locally Advanced Cervical Cancer: A Narrative Review. PMID 42449603 · Cancers (Basel) · 2026-Jun-25 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Risk of bias and clinical benefit of phase III trials supporting FDA-approved anticancer medicines, 2018-2025: A cross-sectional analysis. PMID 42442095 · Eur J Cancer · 2026-Jun-25 The record is a cross-sectional review/meta-analysis of multiple trials, not an original primary report of a single trial. Therefore, it is excluded.
S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prognostic markers, quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active symptom control (ASC) alone or ASC with oxaliplatin-5-FU chemotherapy (ASC + FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 clinical trial. PMID 42349245 · ESMO Open · 2026-Jun-25 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H L S B
旧组与严格 v3 交集 eligibleexplicit_phase3_randomized needs_review 1 Figure · 1 Panel · risk unclear
Renoir phase III Rituximab-Lenalidomide vs Rituximab as Maintenance Treatment in Relapsed/Refractory Follicular Lymphoma. PMID 42349017 · Blood Adv · 2026-Jun-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 - metastatic breast cancer: A translational analysis of the GEICAM/2013-02 PEARL trial. PMID 42202479 · Eur J Cancer · 2026-Jun-25 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
A randomized trial of GVHD prophylaxis in haploidentical PBSC transplantation: ATG, PTCy, and low-dose combination therapy. PMID 41849227 · Blood · 2026-Jun-25 The trial is a Phase III randomized trial in oncology patients (AML/MDS) with time-to-event endpoints. However, the intervention is for GVHD prophylaxis using immunosuppressive agents (ATG, cyclophosphamide) in the transplant setting, not as a primary anticancer drug therapy. Therefore, it does not meet the criterion of a drug-containing intervention for treating malignant neoplasm.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A multicenter randomized phase III trial of weekly cisplatin chemoradiotherapy versus radiotherapy in elderly patients with head and neck squamous cell carcinoma unfit for high-dose cisplatin: JCOG2405 (ELDER-WEEKLY). PMID 42341154 · Jpn J Clin Oncol · 2026-Jun-24 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trial. PMID 42340618 · Breast Cancer · 2026-Jun-24 The report is a quality-of-life analysis from a Phase III randomized trial with a drug intervention and time-to-event endpoint, but it does not present primary or key secondary time-to-event efficacy results (e.g., OS, PFS).
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of hydrocolloid dressing for hand-foot skin reaction: J-SUPPORT 1701 APRON trial. PMID 42337018 · Support Care Cancer · 2026-Jun-23 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type no_km 0 Figure · 0 Panel · risk not_applicable
How will PLUDO, PSMAfore, SPLASH, and ECLIPSE Impact Prostate Cancer Management? PMID 42336749 · Eur Urol Focus · 2026-Jun-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Non-Metastatic Squamous Cell Carcinoma of the Oropharynx: Primary Surgery or (Chemo)radiotherapy? PMID 42333037 · Head Neck · 2026-Jun-22 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Non-thermal focused ultrasound with FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer: An explorative phase II trial. PMID 42335570 · Eur J Cancer · 2026-Jun-20 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Treatment-aware deep learning enables counterfactual prediction of individual benefit from PARP inhibitors in ovarian cancer. PMID 42323410 · NPJ Digit Med · 2026-Jun-20 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial. PMID 42323390 · Prostate Cancer Prostatic Dis · 2026-Jun-20 The report is a subgroup analysis (Black patients) from a Phase III randomized trial (ARANOTE) with a time-to-event endpoint (rPFS) and a drug intervention (darolutamide). However, it is not an original formal result report of the primary trial population; it is a pre-specified subgroup analysis.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study. PMID 42225112 · Lancet · 2026-Jun-20 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial. PMID 42217458 · Lancet · 2026-Jun-20 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial. PMID 41980234 · J Clin Oncol · 2026-Jun-20 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
First-line atezolizumab monotherapy vs . single-agent chemotherapy in patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum-based therapy: Analysis of the IPSOS Asian subpopulation. PMID 41424028 · Chin Med J (Engl) · 2026-Jun-20 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 2 Figure · 2 Panel · risk unclear
IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma. PMID 42317052 · Future Oncol · 2026-Jun-19 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H L S B
旧组与严格 v3 交集 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Maintenance Therapy in Acute Myeloid Leukemia: Current Perspectives and Future Directions. PMID 42346269 · Curr Oncol · 2026-Jun-18 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Adverse events associated with immune checkpoint inhibitors in cervical cancer: A systematic review and meta-analysis of randomized controlled trials. PMID 42320227 · Eur J Obstet Gynecol Reprod Biol · 2026-Jun-18 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Integrating Structured Expert Elicitation with External Evidence to Inform Earlier Reimbursement Decisions: A Norwegian Case Study of Selpercatinib for Non-Small Cell Lung Cancer. PMID 42315785 · Pharmacoecon Open · 2026-Jun-18 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A multicenter randomized phase II/III trial of salvage treatment for refractory primary central nervous system lymphoma using tirabrutinib: JCOG2314 (ReSTART). PMID 42315131 · Jpn J Clin Oncol · 2026-Jun-18 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
[177Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: The AGITG CONTROL NETS Multi-centre randomized trial. PMID 42142431 · Eur J Cancer · 2026-Jun-18 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H L S B
旧组与严格 v3 交集 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis. PMID 41915772 · Blood · 2026-Jun-18 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial. PMID 41911073 · Blood · 2026-Jun-18 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial. PMID 42307937 · JAMA · 2026-Jun-17 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Co-designing primary and secondary outcome measures for an international phase 3 trial of surgical de-escalation in vulvar cancer through a consumer workshop. PMID 42298648 · Res Involv Engagem · 2026-Jun-15 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma: Japan subgroup analysis of the phase III SUNMO trial. PMID 42298056 · Int J Clin Oncol · 2026-Jun-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-year Results From Phase 3 EMPOWER-Lung 3 Part 2 Trial. PMID 42297188 · J Thorac Oncol · 2026-Jun-15 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed